Selected Start-Ups (6/01)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: Archemix Corp. will use its proprietary nucleic acid engineering technology to build protein detection chips and multiplexed assays for use in drug discovery. Gel-Del Technologies Inc. is developing protein-based biomaterials for making implanted medical devices more acceptable to the human body. Neuro Therapeutics Inc. was spun out of the University of British Columbia to commercialize therapies for stimulating repair of injured neurons after traumatic injury of the spinal cord or brain. OncoGenex Technologies Inc. aims to develop and commercialize therapeutics for hormone-independent prostate cancer. Rejuvenon Corp. aims to turn back the hands of time with drugs to treat or prevent disorders related to aging. A new entrant in the cardiovascular diagnostics arena, Belgium's Thermocore Medical Systems NV is developing a thermographic catheter-based system to localize and visualize unstable coronary plaque.
You may also be interested in...
Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK Aims To Launch 13 Blockbusters In Five Years
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
Need a specific report? 1000+ reports available
Buy Reports